Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
ANDA Approval Records Likely To End
Record Approvals Expected To End As US FDA Mops Up Backlog
Dec 09 2019
•
By
Derrick Gingery
Once the backlog is cleared, there may be fewer ANDAs for FDA to approve, which may mean records will not continue to be broken each year • Source: Shutterstock
More from Regulation
More from Policy & Regulation